NASDAQ:SRPT Sarepta Therapeutics Q3 2026 Earnings Report $18.21 +0.71 (+4.06%) Closing price 04:00 PM EasternExtended Trading$17.85 -0.36 (-1.99%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sarepta Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.14Beat/MissN/AOne Year Ago EPSN/ASarepta Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$353.84 millionBeat/MissN/AYoY Revenue GrowthN/ASarepta Therapeutics Announcement DetailsQuarterQ3 2026Date11/4/2026TimeAfter Market ClosesConference Call DateMonday, November 2, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Sarepta Therapeutics Earnings HeadlinesJim Cramer Explains His Hesitation Over Sarepta (SRPT) TherapeuticsOctober 7 at 9:05 PM | finance.yahoo.comJim Cramer Explains His Hesitation Over Sarepta (SRPT) TherapeuticsOctober 7 at 7:31 PM | insidermonkey.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.October 8 at 1:00 AM | Golden Portfolio (Ad)Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Zacks ResearchOctober 7 at 7:31 AM | americanbankingnews.comJim Cramer: This tech stock is 'very good,' Avery Dennison is a 'winner'October 6 at 1:02 PM | msn.comReviewing AbCellera Biologics (NASDAQ:ABCL) & Sarepta Therapeutics (NASDAQ:SRPT)October 6 at 12:15 PM | americanbankingnews.comSee More Sarepta Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sarepta Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sarepta Therapeutics and other key companies, straight to your email. Email Address About Sarepta TherapeuticsSarepta Therapeutics (NASDAQ:SRPT) (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders. The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy. The availability and approved uses of these products may vary by jurisdiction and patient population. Sarepta was originally established as AntiVirals and later operated as AVI BioPharma before adopting the Sarepta Therapeutics name in 2012. Headquartered in Cambridge, Massachusetts, the company conducts research and commercial activities in the United States and serves patients and healthcare providers through its therapies and related support programs, while continuing to develop treatments for additional rare genetic diseases.View Sarepta Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
